glp-1 agonist medications Holding Agonists Prior to Elective Procedures GLP-1 Drug Savings: A Complete

While no differences in kidney mass were noted across all groups, there was a slight, yet significant difference in kidney glycogen levels in both allulose groups

There is also a need to know if all GLP-1Ra have the same impact on bone outcomes

At the pancreas, it potentiates glucose-stimulated insulin secretion while suppressing glucagon release, thereby lowering circulating glucose concentrations

SUSTAIN-6 evaluated once-weekly semaglutide versus placebo in patients at moderate and high cardiovascular risk with type 2 diabetes, showing a 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95)

Please consult your physician for medical advice

Adapted from Wadden et al